Utilization of Direct Smears of Thyroid Fine-needle Aspirates for Ancillary Molecular Testing: A Comparison of Two Proprietary Testing Platforms

Partyka, Kristen L.; Randolph, Melissa; Lawrence, Karen A.; Cramer, Harvey; Wu, Hao

doi:10.1016/j.jasc.2017.06.184

Cited by 2 publications

(6 citation statements)

References 13 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46 The initial validation studies and our personal experience support its utility as a rule-out test based on the miRNA expression profile in thyroid aspirates. 17,20,21,23 Additionally,…”

Section: Resultsmentioning

confidence: 99%

“…To provide more options, we recently performed a study to evaluate routinely stained cytology smears with platforms from Rosetta Genomics and Interpace Diagnostics. [20][21][22][23] Our clinicians have decided to request Afirma as the primary test and Interpace as an alternate when necessary.…”

Section: Methodsmentioning

confidence: 99%

“…18,19,21,26 We applied a similar approach and incorporated all indeterminate aspirates during our internal validation of Rosetta and Interpace. 23 A SM diagnosis (Bethesda V) implies a high pretest probability of malignancy and directly impacts the test performance. For statistical purposes, the aspirates of SM were excluded from the final evaluation.…”

Section: Methodsmentioning

confidence: 99%

“…[20][21][22] We previously conducted a retrospective study to evaluate the use of direct smears with these platforms. 23 function. 17,24 Several publications have reported unique patterns of miRNA expression in different tumors, including thyroid cancer.…”

Section: Introductionmentioning

confidence: 99%

“…The decision to perform molecular testing can potentially be made after the time of procurement. 23 Molecular pathology is a rapidly expanding field. Updates to the ThyGenX panel were launched in 2017 with supplemental testing for mutations in the telomerase reverse transcriptase (TERT) gene.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine‐needle aspiration

Partyka

Trevino

Randolph

et al. 2019

Diagnostic Cytopathology

Self Cite

View full text Add to dashboard Cite

BACKGROUND The management of thyroid nodules with indeterminate cytology is challenging. Recently, molecular testing on fine‐needle aspirates (FNAs) has been advocated to determine whether clinical follow‐up or surgery is warranted for patients. Three different testing platforms were performed on aspirates from our institution (Afirma Thyroid FNA Analysis, RosettaGX Reveal, and Interpace ThyGenX/ThyraMIR). This study compares their diagnostic efficacy. METHODS We conducted a retrospective analysis of indeterminate thyroid FNAs with correlating molecular testing over 4 years (2015‐2018). The aspirates included diagnoses of follicular lesion of undetermined significance, follicular neoplasm, or suspicious for malignancy (SM). Based on cases that underwent surgical resection (Afirma, n = 37; Rosetta, n = 19; Interpace, n = 14), we calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for risk of malignancy and neoplasia. RESULTS The three tests performed similarly when predicting risk of malignancy. They showed high sensitivity (80‐100%) and NPV (90‐100%) but lower specificity (10‐64%) and PPV (21‐44%). When assessing their value to predict neoplasia, each test had a high PPV (76‐89%) but low NPV (20‐33%). The sensitivity for neoplasm was intermediate to high (50‐93%), and the specificity remained extremely variable (11‐67%). CONCLUSION Overall, these molecular platforms performed similarly, displaying high NPV but low to intermediate PPV for malignancy and low NPV but high PPV for neoplasm. The risk of neoplasm is a good index for surgery, and we argue that many of the neoplasms are low‐risk tumors. We endorse conservative treatment with lobectomy for cases that are indeterminate at FNA but suspicious by molecular testing.

show abstract

“…46 The initial validation studies and our personal experience support its utility as a rule-out test based on the miRNA expression profile in thyroid aspirates. 17,20,21,23 Additionally,…”

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine‐needle aspiration

Partyka

Trevino

Randolph

et al. 2019

Diagnostic Cytopathology

Self Cite

View full text Add to dashboard Cite

show abstract

Current and future markers for the diagnosis of thyroid cancer

raldine¹,

Journé²,

Saussez³

2019

COR

View full text Add to dashboard Cite

Today, immunohistochemical markers are routinely used alone or in association to examine thyroid lesions but without sufficient sensitivity and specificity regarding to cancer diagnosis. Additional markers are currently identified among genetic alterations or miRNA panels carrying significant diagnostic values. Combining immunostaining data, mutation status, gene rearrangement and miRNA expression should help to define an integrative signature for the accurate diagnosis of thyroid carcinomas.

show abstract

Utilization of Direct Smears of Thyroid Fine-needle Aspirates for Ancillary Molecular Testing: A Comparison of Two Proprietary Testing Platforms

Cited by 2 publications

References 13 publications

Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine‐needle aspiration

Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine‐needle aspiration

Current and future markers for the diagnosis of thyroid cancer

Contact Info

Product

Resources

About